Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings

Preventing Chronic Disease

Volumn 2, Issue 3, 2005, Pages

  O'Connor, Patrick J ^a   Gray, Richard J ^a   Maciosek, Michael V ^a   Fillbrandt, Kelly M ^a   DeFor, Terese A ^a   Alexander, Charles M ^b   Weiss, Thomas W ^b   Teutsch, Steven M ^b  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; CLINICAL PRACTICE; COMORBIDITY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; SOCIOECONOMICS; STATISTICS; UNITED STATES;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SOCIOECONOMIC FACTORS;

EID: 33747430545     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9.
3. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004;110:386-91.
4. Larosa JC, Grundy MD, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1-11.
5. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102(16):1893-900.
6. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
8. Arnett DK, McGovern PG, Jacobs DR, Shahar E, Duval S, Blackburn H, et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): The Minnesota heart survey. Am J Epidemiol 2002 Nov 15;156(10):929-35.
9. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC, Jr, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83(9):1303-7.
10. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-67.
11. Institute for Clinical Systems Improvement. Health care guideline: treatment of lipid disorder in adults. Bloomington (MN): Institute for Clinical Systems Improvement; 2000 Nov.
12. Carleton RA, Dwyer J, Finberg L, Flora J, Goodman DS, Grundy SM, et al. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 1991;83:2154-232.
13. O'Connor P, Rush W, Pronk N, Cherney L. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care 1998;4(3):335-42.
14. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29(3):538-42.
15. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of highdensity-lipoprotein cholesterol. Clin Chem 1982;28(6):1379-88.
16. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20(4):470-5.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.
18. Dilman DA. Mail and telephone surveys: the total design method: Indianapolis (IN): John Wiley & Sons, Inc; 1978.
19. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332(17):1125-31.
20. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288(4):455-61.
21. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462-7.
22. Sperl-Hillen J, O'Connor PJ, Carlson RR, Lawson TB, Halstenson C, Crowson T, et al. Improving diabetes care in a large health care system: an enhanced primary care approach. Jt Comm J Qual Improv 2000;26(11):615-22.
23. O'Connor PJ, Rush WA, Rardin KA, Isham G. Are HMO members willing to engage in two-way communication to improve health? HMO Pract 1996;10(1):17-9.
24. O'Connor PJ, Rush WA, Peterson J, Morben P, Cherney L, Keogh C, et al. Continuous quality improvement can improve glycemic control for HMO patients with diabetes. Arch Fam Med 1996;5(9):502-6.
25. O'Connor PJ, Desai J, Rush WA, Cherney LM, Solberg LI, Bishop DB. Is having a regular provider of diabetes care related to intensity of care and glycemic control? J Fam Pract 1998;47(4):290-7.
26. O'Connor P, Pronk N, Tan A, Rush W, Gray R. Does professional advice influence aspirin use to prevent heart disease in an HMO population? EffClin Pract 1998;1(1):26-32.
27. Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med 2002;162(9):1013-9.
28. Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM. Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. Arch Intern Med 2001;161(12):1521-8.